MC
XLO icon

Merck & Co’s Xilio Therapeutics XLO Stock Holding History

Merck & Co’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Hold
105,982
– – 0.19% 11
2026
Q1 		$891K Sell
105,982
-1
-0% -$8 0.26% 11
2025
Q4 		$950K Hold
105,983
– – 0.34% 9
2025
Q3 		$1.25M Hold
105,983
– – 0.55% 10
2025
Q2 		$1.01M Hold
105,983
– – 0.47% 10
2025
Q1 		$1.07M Hold
105,983
– – 0.65% 10
2024
Q4 		$1.42M Buy
+105,983
New +$1.46M 0.55% 9

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Merck & Co's XLO Position: Q2 2026 in Review

Merck & Co held its Xilio Therapeutics (XLO) position steady in Q2 2026 at 105,982 shares worth $1.02M. The position accounts for 0.19% of the portfolio, ranked #11.

Merck & Co first reported a position in XLO in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.42M in Q4 2024. 27 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Merck & Co held 105,982 shares of Xilio Therapeutics worth $1.02M as of Q2 2026.
  • Merck & Co left its Xilio Therapeutics share count unchanged in Q2 2026.
  • Xilio Therapeutics made up 0.19% of Merck & Co's portfolio in Q2 2026, its #11 holding.
  • Merck & Co first reported a position in Xilio Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Merck & Co's Xilio Therapeutics position peaked at $1.42M in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Merck & Co's 13F filing for Q2 2026, filed 7 Aug 2026.